Flexion Therapeutics Priced, Nasdaq: FLXN
Developing sustained-release injectable pain therapies for osteoarthritis.
Industry: Health Care
First Day Return: +13.2%
FLXN
Developing sustained-release injectable pain therapies for osteoarthritis.
| IPO Data | |
|---|---|
| IPO Date | 02/11/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $65 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Burlington, MA, United States |
| Founded | 2007 |
| Employees at IPO | 16 |
| Website www.flexiontherapeutics.com | |
IPO News for Flexion Therapeutics
Flexion Therapeutics (FLXN) Performance
